View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBellerophon Therapeutics 将来の成長Future 基準チェック /06現在、 Bellerophon Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.61m to US$4.22m. Losses expected to increase from US$1.06 per share to US$1.28. Biotechs industry in the US expected to see average net income decline 84% next year. Consensus price target of US$10.50 unchanged from last update. Share price fell 87% to US$0.90 over the past week.Price Target Changed • Jun 02Price target decreased by 8.0% to US$25.75Down from US$28.00, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$6.89. Stock is up 550% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$2.08 last year.Major Estimate Revision • May 22Consensus revenue estimates increase by 157%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$2.39m to US$6.14m. Forecast losses expected to reduce from -US$1.75 to -US$0.907 per share. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$28.00 unchanged from last update. Share price fell 9.1% to US$7.92 over the past week.Major Estimate Revision • Apr 05Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.49m to US$3.59m. Forecast losses increased from -US$1.69 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target of US$24.50 unchanged from last update. Share price rose 49% to US$11.40 over the past week.Breakeven Date Change • Apr 02Forecast to breakeven in 2025The 2 analysts covering Bellerophon Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$13.5m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.Price Target Changed • Nov 16Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 2,107% above last closing price of US$1.11. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.07 next year compared to a net loss per share of US$1.87 last year.すべての更新を表示Recent updatesお知らせ • Mar 07Bellerophon Therapeutics, Inc. Files Form 15Bellerophon Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.お知らせ • Nov 22+ 1 more updateBellerophon Therapeutics, Inc. Announces Executive ChangesBellerophon Therapeutics, Inc. announced that each of Peter Fernandes, the Company’s Chief Executive Officer, principal executive officer and principal financial officer, and Parag Shah, the Company’s Vice President of Business Operations, the board of directors of the Company set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah. The material terms of the transition and separation agreements were previously disclosed in the Company’s Current Report on Form 8-K filed on August 7, 2023. On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023, to serve until the next election of directors and thereafter until his successor has been elected and qualified or until his earlier death, resignation or removal. Mr. Jalbert has not been appointed to any committee of the Board and as of the date hereof is not expected to be appointed to any committee of the Board.お知らせ • Oct 14+ 1 more updateBellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's BoardOn October 12, 2023, Theodore Wang notified the board of directors of Bellerophon Therapeutics, Inc. (the Company") of his resignation as a member of the Company's Board, effective immediately.New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 23% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings are forecast to decline by an average of 38% per year for the foreseeable future. Market cap is less than US$10m (US$1.25m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Shareholders have been diluted in the past year (28% increase in shares outstanding).New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings are forecast to decline by an average of 38% per year for the foreseeable future. Market cap is less than US$10m (US$4.81m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Shareholders have been diluted in the past year (28% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).New Risk • Aug 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 36% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (US$4.79m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$13m net loss next year). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).お知らせ • Jul 25Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain ComplianceOn July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the opening of business on July 28, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process.お知らせ • Jul 15Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of DirectorOn July 10, 2023, Crispin Teufel, a member of the board of directors of Bellerophon Therapeutics, Inc. notified the board that he will resign as a director of the company and its subsidiaries, effective immediately. Mr. Teufel’s decision to resign is not due to any disagreement with the company on any matters relating to the company’s operations, policies, or practices.New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$9.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Market cap is less than US$10m (US$7.21m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$7.9m net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.61m to US$4.22m. Losses expected to increase from US$1.06 per share to US$1.28. Biotechs industry in the US expected to see average net income decline 84% next year. Consensus price target of US$10.50 unchanged from last update. Share price fell 87% to US$0.90 over the past week.お知らせ • Jun 06Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD). The REBUILD clinical trial was designed as a randomized, double-blind, placebo-controlled Phase 3 study evaluating the safety and efficacy of INOpulse® for the treatment of patients with fILD. A total of 145 fILD patients were enrolled and treated with either INOpulse® at a dose of iNO45 or a placebo. The primary endpoint was the change in moderate to vigorous physical activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. The trial did not meet its primary endpoint, with iNO45 performing worse than placebo by 5.49 minutes per day (p=0.2646). The secondary endpoints demonstrated minimal difference between the two groups with none approaching statistical significance. Overall, INOpulse® was well-tolerated with no safety concerns, consistent with what has been observed in the prior Phase 2 studies. Key REBUILD clinical trial secondary endpoints and safety outputs assessed over 16 weeks of blinded treatment included: Overall Activity showed 3.51 count/min benefit in favor of iNO45 (p=0.8572) 6 Minute Walk Distance showed 0.19 meter benefit in favor of iNO45 (p=0.9866) Patient reported outcomes (St. George’s Respiratory Questionnaire and UCSD Shortness of Breath) were slightly in favor of placebo, while time to event assessments (Clinical Worsening, Clinical Deterioration and Clinical Improvement) showed little difference and none were statistically significant Subjects with treatment emergent adverse events was slightly in favor of placebo (84.0% vs 74.3%) Subjects with serious treatment emergent adverse events was balanced (20% vs 21.4%) Deaths were balanced (4.0% vs 4.3%).Price Target Changed • Jun 02Price target decreased by 8.0% to US$25.75Down from US$28.00, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$6.89. Stock is up 550% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$2.08 last year.Recent Insider Transactions • May 24Insider recently sold US$82k worth of stockOn the 18th of May, Bobae Kim sold around 8k shares on-market at roughly US$10.00 per share. This transaction amounted to 83% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Major Estimate Revision • May 22Consensus revenue estimates increase by 157%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$2.39m to US$6.14m. Forecast losses expected to reduce from -US$1.75 to -US$0.907 per share. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$28.00 unchanged from last update. Share price fell 9.1% to US$7.92 over the past week.お知らせ • May 12Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. The REBUILD study is a Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo. The Phase 3 program builds on the results from the Company’s previously reported Phase 2 studies which showed improvement in multiple cardiopulmonary parameters, including pulmonary vascular resistance after acute treatment and benefit in Moderate to Vigorous Physical Activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy. If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.Major Estimate Revision • Apr 05Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.49m to US$3.59m. Forecast losses increased from -US$1.69 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target of US$24.50 unchanged from last update. Share price rose 49% to US$11.40 over the past week.Breakeven Date Change • Apr 02Forecast to breakeven in 2025The 2 analysts covering Bellerophon Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$13.5m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.お知らせ • Feb 10Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.お知らせ • Jan 19Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company now expects to report pivotal top-line results in mid- 2023. The REBUILD study is a pivotal Phase 3, randomized, double-blind, placebo-controlled dose escalation and verification clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy, based on the results from Phase 2, and will be the basis for the submission of NDA for approval in fILD.分析記事 • Jan 06Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Nov 16Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 2,107% above last closing price of US$1.11. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.07 next year compared to a net loss per share of US$1.87 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Sep 27Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study sizeBellerophon Therapeutics (NASDAQ:BLPH) on Tuesday said the U.S. FDA had accepted the company's proposal to reduce the study size of its ongoing phase 3 trial of its nitric oxide treatment for fibrotic interstitial lung disease (fILD). Shares of the micro-cap clinical-stage biotherapeutics company rose 23.7% to $1.20 in morning trading. ILD refers to a group of chronic lung diseases in which inflammation and scarring make it hard for the lungs to get enough oxygen. The new study size for the late-stage trial, called REBUILD, was 140 patients, BLPH said in a statement, adding that the change does not impact the trial objective or goals. An independent data monitoring committee also agreed to the new targeted study size. Enrollment in the late-stage trial is now expected to end in Q1 2023, with data readout anticipated in Q3 2023.Seeking Alpha • Aug 15Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17Bellerophon Therapeutics press release (NASDAQ:BLPH): Q2 GAAP EPS of -$0.43 beats by $0.17. As of June 30, 2022, the Company had cash and cash equivalents of $16.3 million, compared to cash and cash equivalents of $24.7 million at December 31, 2021.Price Target Changed • Apr 27Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 1,601% above last closing price of US$1.44. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.16 next year compared to a net loss per share of US$1.87 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jan 18Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Executive Departure • Sep 14CFO & Secretary Assaf Korner has left the companyOn the 10th of September, Assaf Korner's tenure as CFO & Secretary ended. As of June 2021, Assaf still personally held only 4.41k shares (US$21k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 5.13 years.Price Target Changed • Sep 03Price target decreased to US$25.00Down from US$37.50, the current price target is an average from 3 analysts. New target price is 510% above last closing price of US$4.10. Stock is down 59% over the past year. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Bellerophon Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:BLPH - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20236-9-12-12N/A6/30/20236-12-11-11N/A3/31/20236-11-10-10N/A12/31/2022N/A-20-18-18N/A9/30/2022N/A-19-17-17N/A6/30/2022N/A-19-18-18N/A3/31/2022N/A-18-20-20N/A12/31/2021N/A-18-23-23N/A9/30/2021N/A-21-25-25N/A6/30/2021N/A-25-25-25N/A3/31/2021N/A-25-23-23N/A12/31/2020N/A-25-20-20N/A9/30/2020N/A-21-16-16N/A6/30/2020N/A-17-15-15N/A3/31/2020N/A-17-15-15N/A12/31/2019N/A-13-13-13N/A9/30/2019N/A-10-14-14N/A6/30/2019N/A5-16-16N/A3/31/2019N/A-2-17-17N/A12/31/2018N/A3-15-15N/A9/30/2018N/A-20-16-16N/A6/30/2018N/A-39-14-14N/A3/31/2018N/A-32-13-13N/A12/31/2017N/A-55-16-16N/A9/30/2017N/A-38-14-14N/A6/30/2017N/A-35N/A-14N/A3/31/2017N/A-36N/A-14N/A12/31/2016N/A-24N/A-17N/A9/30/2016N/A-27N/A-32N/A6/30/2016N/A-34N/A-40N/A3/31/2016N/A-41N/A-44N/A12/31/2015N/A-46N/A-46N/A9/30/2015N/A-48N/A-41N/A6/30/2015N/A-53N/A-45N/A3/31/2015N/A-58N/A-49N/A12/31/2014N/A-60N/A-71N/A9/30/2014N/A-64N/A-71N/A3/31/2014N/A-62N/A-72N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BLPHの予測収益成長が 貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BLPHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BLPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BLPHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BLPHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BLPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/20 19:06終値2024/12/18 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bellerophon Therapeutics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Sally YanchusBrookline Capital MarketsAndrew FeinH.C. Wainwright & Co.Christopher HowertonJefferies LLC7 その他のアナリストを表示
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.61m to US$4.22m. Losses expected to increase from US$1.06 per share to US$1.28. Biotechs industry in the US expected to see average net income decline 84% next year. Consensus price target of US$10.50 unchanged from last update. Share price fell 87% to US$0.90 over the past week.
Price Target Changed • Jun 02Price target decreased by 8.0% to US$25.75Down from US$28.00, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$6.89. Stock is up 550% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$2.08 last year.
Major Estimate Revision • May 22Consensus revenue estimates increase by 157%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$2.39m to US$6.14m. Forecast losses expected to reduce from -US$1.75 to -US$0.907 per share. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$28.00 unchanged from last update. Share price fell 9.1% to US$7.92 over the past week.
Major Estimate Revision • Apr 05Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.49m to US$3.59m. Forecast losses increased from -US$1.69 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target of US$24.50 unchanged from last update. Share price rose 49% to US$11.40 over the past week.
Breakeven Date Change • Apr 02Forecast to breakeven in 2025The 2 analysts covering Bellerophon Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$13.5m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
Price Target Changed • Nov 16Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 2,107% above last closing price of US$1.11. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.07 next year compared to a net loss per share of US$1.87 last year.
お知らせ • Mar 07Bellerophon Therapeutics, Inc. Files Form 15Bellerophon Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.
お知らせ • Nov 22+ 1 more updateBellerophon Therapeutics, Inc. Announces Executive ChangesBellerophon Therapeutics, Inc. announced that each of Peter Fernandes, the Company’s Chief Executive Officer, principal executive officer and principal financial officer, and Parag Shah, the Company’s Vice President of Business Operations, the board of directors of the Company set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah. The material terms of the transition and separation agreements were previously disclosed in the Company’s Current Report on Form 8-K filed on August 7, 2023. On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023, to serve until the next election of directors and thereafter until his successor has been elected and qualified or until his earlier death, resignation or removal. Mr. Jalbert has not been appointed to any committee of the Board and as of the date hereof is not expected to be appointed to any committee of the Board.
お知らせ • Oct 14+ 1 more updateBellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's BoardOn October 12, 2023, Theodore Wang notified the board of directors of Bellerophon Therapeutics, Inc. (the Company") of his resignation as a member of the Company's Board, effective immediately.
New Risk • Oct 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 23% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings are forecast to decline by an average of 38% per year for the foreseeable future. Market cap is less than US$10m (US$1.25m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Shareholders have been diluted in the past year (28% increase in shares outstanding).
New Risk • Aug 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$11m free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings are forecast to decline by an average of 38% per year for the foreseeable future. Market cap is less than US$10m (US$4.81m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$15m net loss next year). Shareholders have been diluted in the past year (28% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).
New Risk • Aug 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 36% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (US$4.79m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$13m net loss next year). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).
お知らせ • Jul 25Bellerophon Therapeutics to Be Delisted from the Nasdaq Capital Market At Opening of Business on July 28, 2023 Unless It Timely Requests A Hearing Before Nasdaq Hearings Panel to Address Deficiencies and Present Plan to Regain ComplianceOn July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the opening of business on July 28, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process.
お知らせ • Jul 15Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of DirectorOn July 10, 2023, Crispin Teufel, a member of the board of directors of Bellerophon Therapeutics, Inc. notified the board that he will resign as a director of the company and its subsidiaries, effective immediately. Mr. Teufel’s decision to resign is not due to any disagreement with the company on any matters relating to the company’s operations, policies, or practices.
New Risk • Jul 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$9.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Market cap is less than US$10m (US$7.21m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$7.9m net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).
New Risk • Jun 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$19m net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$82k sold).
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.61m to US$4.22m. Losses expected to increase from US$1.06 per share to US$1.28. Biotechs industry in the US expected to see average net income decline 84% next year. Consensus price target of US$10.50 unchanged from last update. Share price fell 87% to US$0.90 over the past week.
お知らせ • Jun 06Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD). The REBUILD clinical trial was designed as a randomized, double-blind, placebo-controlled Phase 3 study evaluating the safety and efficacy of INOpulse® for the treatment of patients with fILD. A total of 145 fILD patients were enrolled and treated with either INOpulse® at a dose of iNO45 or a placebo. The primary endpoint was the change in moderate to vigorous physical activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. The trial did not meet its primary endpoint, with iNO45 performing worse than placebo by 5.49 minutes per day (p=0.2646). The secondary endpoints demonstrated minimal difference between the two groups with none approaching statistical significance. Overall, INOpulse® was well-tolerated with no safety concerns, consistent with what has been observed in the prior Phase 2 studies. Key REBUILD clinical trial secondary endpoints and safety outputs assessed over 16 weeks of blinded treatment included: Overall Activity showed 3.51 count/min benefit in favor of iNO45 (p=0.8572) 6 Minute Walk Distance showed 0.19 meter benefit in favor of iNO45 (p=0.9866) Patient reported outcomes (St. George’s Respiratory Questionnaire and UCSD Shortness of Breath) were slightly in favor of placebo, while time to event assessments (Clinical Worsening, Clinical Deterioration and Clinical Improvement) showed little difference and none were statistically significant Subjects with treatment emergent adverse events was slightly in favor of placebo (84.0% vs 74.3%) Subjects with serious treatment emergent adverse events was balanced (20% vs 21.4%) Deaths were balanced (4.0% vs 4.3%).
Price Target Changed • Jun 02Price target decreased by 8.0% to US$25.75Down from US$28.00, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$6.89. Stock is up 550% over the past year. The company is forecast to post a net loss per share of US$1.06 next year compared to a net loss per share of US$2.08 last year.
Recent Insider Transactions • May 24Insider recently sold US$82k worth of stockOn the 18th of May, Bobae Kim sold around 8k shares on-market at roughly US$10.00 per share. This transaction amounted to 83% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Major Estimate Revision • May 22Consensus revenue estimates increase by 157%The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from US$2.39m to US$6.14m. Forecast losses expected to reduce from -US$1.75 to -US$0.907 per share. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$28.00 unchanged from last update. Share price fell 9.1% to US$7.92 over the past week.
お知らせ • May 12Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. The REBUILD study is a Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo. The Phase 3 program builds on the results from the Company’s previously reported Phase 2 studies which showed improvement in multiple cardiopulmonary parameters, including pulmonary vascular resistance after acute treatment and benefit in Moderate to Vigorous Physical Activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy. If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.
Major Estimate Revision • Apr 05Consensus revenue estimates fall by 20%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$4.49m to US$3.59m. Forecast losses increased from -US$1.69 to -US$1.87 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target of US$24.50 unchanged from last update. Share price rose 49% to US$11.40 over the past week.
Breakeven Date Change • Apr 02Forecast to breakeven in 2025The 2 analysts covering Bellerophon Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$13.5m in 2025. Average annual earnings growth of 56% is required to achieve expected profit on schedule.
お知らせ • Feb 10Bellerophon Therapeutics, Inc. Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse(R) in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse for the treatment of fibrotic interstitial lung disease (fILD) in China. The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.
お知らせ • Jan 19Bellerophon Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseBellerophon Therapeutics, Inc. announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company now expects to report pivotal top-line results in mid- 2023. The REBUILD study is a pivotal Phase 3, randomized, double-blind, placebo-controlled dose escalation and verification clinical trial evaluating the safety and efficacy of pulsed inhaled nitric oxide (iNO) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis on long-term oxygen therapy. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy, based on the results from Phase 2, and will be the basis for the submission of NDA for approval in fILD.
分析記事 • Jan 06Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Nov 16Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 2,107% above last closing price of US$1.11. Stock is down 69% over the past year. The company is forecast to post a net loss per share of US$2.07 next year compared to a net loss per share of US$1.87 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Sep 27Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study sizeBellerophon Therapeutics (NASDAQ:BLPH) on Tuesday said the U.S. FDA had accepted the company's proposal to reduce the study size of its ongoing phase 3 trial of its nitric oxide treatment for fibrotic interstitial lung disease (fILD). Shares of the micro-cap clinical-stage biotherapeutics company rose 23.7% to $1.20 in morning trading. ILD refers to a group of chronic lung diseases in which inflammation and scarring make it hard for the lungs to get enough oxygen. The new study size for the late-stage trial, called REBUILD, was 140 patients, BLPH said in a statement, adding that the change does not impact the trial objective or goals. An independent data monitoring committee also agreed to the new targeted study size. Enrollment in the late-stage trial is now expected to end in Q1 2023, with data readout anticipated in Q3 2023.
Seeking Alpha • Aug 15Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17Bellerophon Therapeutics press release (NASDAQ:BLPH): Q2 GAAP EPS of -$0.43 beats by $0.17. As of June 30, 2022, the Company had cash and cash equivalents of $16.3 million, compared to cash and cash equivalents of $24.7 million at December 31, 2021.
Price Target Changed • Apr 27Price target decreased to US$24.50Down from US$28.00, the current price target is an average from 2 analysts. New target price is 1,601% above last closing price of US$1.44. Stock is down 68% over the past year. The company is forecast to post a net loss per share of US$2.16 next year compared to a net loss per share of US$1.87 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Crispin Teufel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jan 18Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Executive Departure • Sep 14CFO & Secretary Assaf Korner has left the companyOn the 10th of September, Assaf Korner's tenure as CFO & Secretary ended. As of June 2021, Assaf still personally held only 4.41k shares (US$21k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 5.13 years.
Price Target Changed • Sep 03Price target decreased to US$25.00Down from US$37.50, the current price target is an average from 3 analysts. New target price is 510% above last closing price of US$4.10. Stock is down 59% over the past year.